HC Wainwright Issues Positive Forecast for Affimed Earnings

Affimed (NASDAQ:AFMD) – Investment analysts at HC Wainwright upped their FY2024 EPS estimates for Affimed in a research report issued to clients and investors on Wednesday, December 18th. HC Wainwright analyst S. Ramakanth now forecasts that the biopharmaceutical company will earn ($4.28) per share for the year, up from their previous forecast of ($4.31). HC Wainwright currently has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for Affimed’s current full-year earnings is ($4.00) per share. HC Wainwright also issued estimates for Affimed’s Q4 2024 earnings at ($0.93) EPS, Q3 2025 earnings at ($0.91) EPS, Q4 2025 earnings at ($0.67) EPS and FY2025 earnings at ($3.02) EPS.

AFMD has been the topic of a number of other research reports. Wells Fargo & Company decreased their price objective on Affimed from $20.00 to $15.00 and set an “overweight” rating on the stock in a research note on Thursday, December 12th. Stifel Nicolaus reduced their price objective on shares of Affimed from $5.00 to $4.00 and set a “hold” rating on the stock in a research note on Friday, November 15th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Tuesday, November 19th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $13.50.

Affimed Stock Performance

Shares of NASDAQ:AFMD opened at $1.19 on Monday. The company has a current ratio of 1.93, a quick ratio of 1.93 and a debt-to-equity ratio of 0.13. The business’s fifty day moving average price is $2.92 and its two-hundred day moving average price is $4.02. Affimed has a one year low of $1.14 and a one year high of $8.95.

Institutional Trading of Affimed

Institutional investors have recently modified their holdings of the company. Choreo LLC acquired a new stake in Affimed in the 2nd quarter valued at $54,000. Intellectus Partners LLC lifted its position in Affimed by 12.2% during the 3rd quarter. Intellectus Partners LLC now owns 94,361 shares of the biopharmaceutical company’s stock worth $317,000 after acquiring an additional 10,250 shares in the last quarter. FMR LLC boosted its holdings in Affimed by 30.0% in the 3rd quarter. FMR LLC now owns 17,696 shares of the biopharmaceutical company’s stock worth $59,000 after acquiring an additional 4,086 shares during the period. Point72 Asset Management L.P. grew its position in Affimed by 4.6% in the third quarter. Point72 Asset Management L.P. now owns 342,856 shares of the biopharmaceutical company’s stock valued at $1,152,000 after acquiring an additional 15,108 shares in the last quarter. Finally, Jane Street Group LLC purchased a new stake in shares of Affimed during the third quarter valued at approximately $44,000. Hedge funds and other institutional investors own 30.82% of the company’s stock.

About Affimed

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company’s lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid.